GB Sciences reports first quarter revenue of $1.3 million with gross profit of $700 thousand compared to revenue of $69,100 for same period last year
August 15, 2018 08:50 ET
|
GB Sciences, Inc.
Las Vegas, NV, Aug. 15, 2018 (GLOBE NEWSWIRE) -- For the three months that ended June 30, 2018, GB Sciences, Inc. (OTCQB: GBLX) reported revenue of $1,315,284 and gross profit of $734,719. This...
GB Sciences Strengthen Their Current and Future Compliance Programs by Building A Relationship with Adherence Compliance
July 31, 2018 05:30 ET
|
GB Sciences, Inc.
Las Vegas, NV, July 31, 2018 (GLOBE NEWSWIRE) -- GB Sciences, Inc (OTCQB:GBLX) has contracted Adherence Compliance, a leading cannabis compliance software and services firm, for its Chief Compliance...
GB Sciences Files Patent on Cannabis-based Therapies for the Treatment of Asthma, Urinary Cystitis, Hearing Loss, plus Chronic, Inflammatory and Neuropathic Pain
June 27, 2018 05:30 ET
|
GB Sciences, Inc.
Las Vegas, June 27, 2018 (GLOBE NEWSWIRE) -- GB Sciences, Inc. (OTCQB: GBLX) has filed a new provisional patent application on the use of cannabis-based therapies for the manipulation of...
GB Sciences Puts Its Grey Matter To Work Solving The Big Green Riddle...
May 23, 2018 05:30 ET
|
GB Sciences, Inc.
Las Vegas, NV, May 23, 2018 (GLOBE NEWSWIRE) -- GB Sciences, Inc. (OTCQB: GBLX) For large scale adoption of Cannabis in medical formulations the quality, consistency and trust in the raw...
GB Sciences, CEO, John Poss, Joins Everett Jolly on Uptick Newswire’s “Stock Day” Podcast
April 19, 2018 09:00 ET
|
GB Sciences, Inc.
PHOENIX, April 19, 2018 (GLOBE NEWSWIRE) -- GB Sciences, Inc. (OTCQB:GBLX) (“the “Company”), today announced CEO, John Poss, returned to Uptick Newswire’s “Stock Day” podcast with Everett Jolly for...
John Poss, Chief Executive Officer of GB Sciences, Inc., Returns to Uptick Newswire’s “Stock Day” Podcast with Everett Jolly for Operational Update
February 06, 2018 09:00 ET
|
GB Sciences, Inc.
PHOENIX, Feb. 06, 2018 (GLOBE NEWSWIRE) -- GB Sciences, Inc. (OTCQB:GBLX) (the “company”), discusses 2017 achievements and 2018 operations expectations, on Stock Day Podcast with Everett Jolly. “It...
Uptick Newswire “Stock Day” Interviews John Poss CEO of GB Sciences on the Company’s Cannabis Tiers, Medical and Recreational
December 12, 2017 07:30 ET
|
GB Sciences, Inc.
Phoenix, AZ, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Uptick Newswire is the sole producer of the Uptick Network “Stock Day” Podcast and after airing back in January 2016 CEO and host Everett Jolly has...
GB Sciences is Happy
November 13, 2017 05:30 ET
|
GB Sciences, Inc.
Las Vegas, NV, Nov. 13, 2017 (GLOBE NEWSWIRE) -- GB Sciences, Inc. (OTCQB: GBLX) announces that it has met the October gross revenue projection of $500K from the sale of premium flower. Gross sales...
GB Sciences Inducts Scientific Advisory Board: Dr. Andrea Small-Howard of GB Sciences, Dr. Helen Turner of Chaminade University, Dr. Norbert Kaminsky of Michigan State University, and Dr. Carlos Ríos-Bedoya of McLaren Health
November 01, 2017 05:30 ET
|
GB Sciences, Inc.
Las Vegas, NV, Nov. 01, 2017 (GLOBE NEWSWIRE) -- GB Sciences, Inc. (OTCQB: GBLX) inducts a Scientific Advisory Board to provide oversight for product development within GB Sciences’ intellectual...
GB SCIENCES, INC. PARTNERS WITH CURA CANNABIS SOLUTIONS AND ENTERS THE LUCRATIVE CANNABIS OIL MARKET IN NEVADA
October 30, 2017 12:47 ET
|
GB Sciences, Inc.
Las Vegas, NV, October 30, 2017/GLOBE Newswire, Oct. 30, 2017 (GLOBE NEWSWIRE) -- GB Sciences, Inc. (OTCQB: GBLX) and Cura Cannabis Solutions (Cura) have executed a production agreement to produce...